BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 43 found
  Current Search:  iga: 43, deficiency: 132     

HTML
54%
Medical News: Provectus Pharmaceuticals Completes Patient Accrual In Initial Phase 2 Study Of PH-10 For Atopic
Main Category: Dermatology Also Included In: Clinical Trials / Drug Trials email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: 5 (1 votes) Health Professional: Article Opinions:...
Medical News Today:  Jul 2 2009 7:18PM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual In Initial Phase 2 Study Of PH-10 For Atopic Dermatitis
Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

PH-10 is the Company's topical...

Medical News Today:  Jul 2 2009 4:22PM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis....

Pharmacy Choice:  Jul 1 2009 7:51PM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
- Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

PH-10 is the Company's topical...

DiGiTAL50:  Jul 1 2009 3:43PM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Triggers Milestone to Seek Licensing Partner or Co-Developer for Product Subjects applied PH-10 daily for up to four weeks to skin areas affected by atopic dermatitis, with response observed weekly throughout this treatment phase and for one...
Pharma Live:  Jul 1 2009 12:13PM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 St
Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

PH-10 is the Company's topical...

EuroInvestor.co.uk:  Jul 1 2009 11:52AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

PH-10 is the Company's topical...

Genetic Engineering News:  Jul 1 2009 11:51AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Preliminary Analyses Highlight Safety and Efficacy Triggers Milestone to Seek Licensing Partner or Co-Developer for Product KNOXVILLE, Tenn.--(Business Wire)-- Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology...

Reuters:  Jul 1 2009 11:41AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT : ), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

PH-10 is the Company's topical...

PR inside:  Jul 1 2009 11:12AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for
BusinessWire - --Triggers Milestone to Seek Licensing Partner or Co-Developer for Product Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual...

Forbes.com:  Jul 1 2009 11:12AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
s Milestone to Seek Licensing Partner or Co-Developer for Product Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study...

TradingMarkets:  Jul 1 2009 11:03AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
--Triggers Milestone to Seek Licensing Partner or Co-Developer for Product Provectus Pharmaceuticals, Inc.

( OTC BB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase...

RBC Dain Raushcer:  Jul 1 2009 11:01AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
KNOXVILLE, Tenn.

(Business Wire) -- Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic...

Globe Investor:  Jul 1 2009 10:58AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis....

Yahoo! Canada:  Jul 1 2009 10:56AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
--Triggers Milestone to Seek Licensing Partner or Co-Developer for Product Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase...

StockHouse USA:  Jul 1 2009 10:54AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial
Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis.

PH-10 is the Company's topical...

Business Wire via MSN Money:  Jul 1 2009 10:53AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Preliminary Analyses Highlight Safety and Efficacy Triggers Milestone to Seek Licensing Partner or Co-Developer for Product KNOXVILLE, Tenn.

-- (Business Wire) Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology...

Stockwatch:  Jul 1 2009 10:52AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis....

Street Insider:  Jul 1 2009 10:50AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Preliminary Analyses Highlight Safety and Efficacy KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for...

Business Wire via Yahoo!:  Jul 1 2009 10:48AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
Preliminary Analyses Highlight Safety and Efficacy Triggers Milestone to Seek Licensing Partner or Co-Developer for Product KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and...

Business Wire:  Jul 1 2009 10:47AM
Matching: iga
Find similar documents
HTML
54%
Provectus Pharmaceuticals Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc.

(OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis....

Business Wire UK:  Jul 1 2009 10:47AM
Matching: iga
Find similar documents
HTML
54%
Interaction between variants of two glycosyltransferase genes in IgA nephropathy
1Renal Division, Department of Internal Medicine, Peking University First Hospital, Beijing, China 2Peking University Institute of Nephrology, Beijing, China 3Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China 4MOE...
Kidney International:  Jun 30 2009 8:58AM
Matching: iga
Find similar documents
HTML
54%
IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy
Today in Nephropathies...

IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy.

MDLinx:  Jun 27 2009 12:40AM
Matching: iga
Find similar documents
HTML
100%
How To Confirm The Causes Of Iron Deficiency Anemia In Young Women
Iron-deficiency anaemia (IDA) is commonly seen in women aged under 50 years.

The diagnostic workflow in young women affected by IDA is not clearly established.

The British Society of Gastroenterology recommends gastroscopy only in IDA...

Medical News Today:  Jun 25 2009 7:44AM
Matching: iga deficiency
Find similar documents
HTML
54%
Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled T
(Click the title below to leave the MDLinx Network and go to the Journal's Website) American Journal of Nephrology, 06/23/09 Print Save in My Library Free Abstract Cheng J et al.

- The current cumulative evidence suggests that...

MDLinx:  Jun 24 2009 3:26AM
Matching: iga
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.